{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T17:28:56Z","timestamp":1790616536637,"version":"4.1.0"},"update-to":[{"DOI":"10.1002\/14651858.cd005162.pub3","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2017,6,14]],"date-time":"2017-06-14T00:00:00Z","timestamp":1497398400000}}],"reference-count":62,"publisher":"Wiley","issue":"6","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd005162.pub4","type":"journal-article","created":{"date-parts":[[2018,1,9]],"date-time":"2018-01-09T12:36:54Z","timestamp":1515501414000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Terlipressin versus placebo or no intervention for people with cirrhosis and hepatorenal syndrome"],"prefix":"10.1002","volume":"2017","author":[{"given":"Andrew S","family":"Allegretti","sequence":"first","affiliation":[{"name":"Massachusetts General Hospital; Division of Nephrology, Department of Medicine; Boston USA MA 02114"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mads","family":"Israelsen","sequence":"additional","affiliation":[{"name":"Odense University Hospital; Department of Gastroenterology and Hepatology; Sdr. Boulevard 29 Odense C Denmark 5000"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleksander","family":"Krag","sequence":"additional","affiliation":[{"name":"Odense University Hospital; Department of Gastroenterology and Hepatology; Sdr. Boulevard 29 Odense C Denmark 5000"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manol","family":"Jovani","sequence":"additional","affiliation":[{"name":"Massachusetts General Hospital and Harvard Medical School; Division of Gastroenterology; 55 Fruit St Boston USA MA 02114"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison H","family":"Goldin","sequence":"additional","affiliation":[{"name":"Brigham and Women's Hospital; Division of Gastroenterology, Hepatology and Endoscopy; Boston USA MA 02115"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allison R","family":"Schulman","sequence":"additional","affiliation":[{"name":"Brigham and Women's Hospital; Division of Gastroenterology, Hepatology and Endoscopy; Boston USA MA 02115"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel W","family":"Winter","sequence":"additional","affiliation":[{"name":"Brigham and Women's Hospital; Division of Gastroenterology, Hepatology and Endoscopy; Boston USA MA 02115"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lise Lotte","family":"Gluud","sequence":"additional","affiliation":[{"name":"Copenhagen University Hospital Hvidovre; Gastrounit, Medical Division; Kettegaards Alle Hvidovre Denmark 2650"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2017,6,14]]},"reference":[{"key":"10.1002\/14651858.CD005162.pub4-BIB0001|cit1","first-page":"39","article-title":"A randomized, placebo-controlled, double-blind study to confirm the reversal of hepatorenal syndrome type 1 with terlipressin: the REVERSE trial design","volume":"4","author":"Boyer","year":"2012","journal-title":"Open Access Journal of Clinical Trials"},{"key":"10.1002\/14651858.CD005162.pub4-BIB0002|cit2","unstructured":"Boyer TD Sanyal AJ Wong F Frederick RT Lake JR O'Leary JG Terlipressin plus albumin is more effective than albumin alone in improving renal function in patients with cirrhosis and hepatorenal syndrome type 1 Gastroenterology 2016 1579 89.e2"},{"key":"10.1002\/14651858.CD005162.pub4-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"165A","DOI":"10.1016\/0270-9139(95)94386-2","article-title":"Terlipressin in the treatment of hepatorenal syndrome (HRS): a double blind cross-over study","volume":"22","author":"Hadengue","year":"1995","journal-title":"Hepatology (Baltimore, Md.)"},{"key":"10.1002\/14651858.CD005162.pub4-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S0168-8278(98)80151-7","article-title":"Beneficial effects of the 2-day administration of terlipressin in patients with cirrhosis and hepatorenal syndrome","volume":"29","author":"Hadengue","year":"1998","journal-title":"Journal of Hepatology"},{"key":"10.1002\/14651858.CD005162.pub4-BIB0006|cit5","doi-asserted-by":"crossref","first-page":"S36","DOI":"10.1016\/S0168-8278(07)61680-8","article-title":"Randomized, comparative study of terlipressin and albumin vs albumin alone in patients with cirrhosis and hepatorenal syndrome","volume":"46","author":"Martin-Llahi","year":"2007","journal-title":"Journal of Hepatology"},{"key":"10.1002\/14651858.CD005162.pub4-BIB0005|cit6","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1053\/j.gastro.2008.02.024","article-title":"Terlipressin and albumin vs albumin in patients with cirrhosis and hepatorenal syndrome: a randomized study","volume":"134","author":"Mart\u00edn-Llah\u00ed","year":"2008","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD005162.pub4-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1007\/s10620-007-9919-9","article-title":"Terlipressin and albumin in patients with cirrhosis and type I hepatorenal syndrome","volume":"53","author":"Neri","year":"2008","journal-title":"Digestive Diseases and Sciences"},{"key":"10.1002\/14651858.CD005162.pub4-BIB0008|cit8","first-page":"34","article-title":"Low doses of terlipressin and albumin in type I hepatorenal syndrome","volume":"2","author":"Pulvirenti","year":"2008","journal-title":"Italian Journal of Medicine"},{"key":"10.1002\/14651858.CD005162.pub4-BIB0009|cit9","first-page":"694A","article-title":"A prospective, randomized, double blind, placebo-controlled trial of terlipressin for type 1 hepatorenal syndrome (HRS)","volume":"44","author":"Sanyal","year":"2006","journal-title":"Hepatology (Baltimore, Md.)"},{"key":"10.1002\/14651858.CD005162.pub4-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1053\/j.gastro.2008.02.014","article-title":"A randomized, prospective, double-blind, placebo-controlled trial of terlipressin for type 1 hepatorenal syndrome","volume":"134","author":"Sanyal","year":"2008","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD005162.pub4-BIB0011|cit11","first-page":"1071A","article-title":"Effect of terlipressin on mean arterial pressure (MAP) and its relation to serum creatinine concentration in type 1 hepatorenal syndrome (HRS): analysis of data from the pivotal phase 3 trial","volume":"48","author":"Sanyal","year":"2008","journal-title":"Hepatology (Baltimore, Md.)"},{"key":"10.1002\/14651858.CD005162.pub4-BIB0012|cit12","first-page":"565A","article-title":"Prognostic factors for hepatorenal syndrome (HRS) in patients with type 1 HRS enrolled in a randomized double-blind, placebo-controlled trial","volume":"46","author":"Sanyal","year":"2007","journal-title":"Hepatology (Baltimore, Md.)"},{"key":"10.1002\/14651858.CD005162.pub4-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1046\/j.1440-1746.2003.02934.x","article-title":"Beneficial effects of terlipressin in hepatorenal syndrome: a prospective, randomized placebo-controlled clinical trial","volume":"18","author":"Solanki","year":"2003","journal-title":"Journal of Gastroenterology and Hepatology"},{"key":"10.1002\/14651858.CD005162.pub4-BIB0014|cit14","first-page":"123","article-title":"Efficacy of terlipressin in treatment of liver cirrhosis with hepatorenal syndrome","volume":"7","author":"Yang","year":"2001","journal-title":"Journal of Internal Intensive Medicine"},{"key":"10.1002\/14651858.CD005162.pub4-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"S175","DOI":"10.14309\/00000434-201210001-00418","article-title":"Role of terlipressin and albumin combination versus albumin alone in hepatorenal syndrome","volume":"107","author":"Zafar","year":"2012","journal-title":"American Journal of Gastroenterology"},{"key":"10.1002\/14651858.CD005162.pub4-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"S83","DOI":"10.1016\/S0168-8278(06)80204-7","article-title":"Noradrenaline vs terlipressin in hepatorenal syndrome: a prospective, randomized study","volume":"44","author":"Alessandria","year":"2006","journal-title":"Journal of Hepatology"},{"key":"10.1002\/14651858.CD005162.pub4-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.jhep.2007.04.010","article-title":"Noradrenalin vs terlipressin in patients with hepatorenal syndrome: a prospective, randomized, unblinded, pilot study","volume":"47","author":"Alessandria","year":"2007","journal-title":"Journal of Hepatology"},{"key":"10.1002\/14651858.CD005162.pub4-BIB0018|cit18","first-page":"378A","article-title":"Terlipressin given as continuous intravenous infusion is the more suitable schedule for the treatment of type 1 hepatorenal syndrome (HRS) in patients with cirrhosis: results of a controlled clinical study","volume":"48","author":"Angeli","year":"2008","journal-title":"Hepatology (Baltimore, Md.)"},{"key":"10.1002\/14651858.CD005162.pub4-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"S10","DOI":"10.1016\/S1590-8658(12)60030-9","article-title":"Terlipressin and albumin vs midodrine plus octreotide in the treatment of hepatorenal syndrome in patients with cirrhosis: results of a controlled trial by the Italian Association for the Study of the Liver","volume":"44","author":"Cavallin","year":"2012","journal-title":"Digestive and Liver Disease"},{"key":"10.1002\/14651858.CD005162.pub4-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1002\/hep.27709","article-title":"Terlipressin plus albumin versus midodrine and octreotide plus albumin in the treatment of hepatorenal syndrome: a randomized trial","volume":"62","author":"Cavallin","year":"2015","journal-title":"Hepatology (Baltimore, Md.)"},{"key":"10.1002\/14651858.CD005162.pub4-BIB0021|cit21","first-page":"S56","article-title":"Captopril in low dose associated with octreotide in hepatorenal syndrome: a randomized study","volume":"38","author":"Chelarescu","year":"2003","journal-title":"Journal of Hepatology"},{"key":"10.1002\/14651858.CD005162.pub4-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"S97","DOI":"10.1016\/j.jceh.2013.02.242","article-title":"Noradrenaline is equally effective as terlipressin in reversal of type 1 hepatorenal syndrome: a randomized prospective study","volume":"3","author":"Indrabi","year":"2013","journal-title":"Journal of Clinical and Experimental Hepatology"},{"key":"10.1002\/14651858.CD005162.pub4-BIB0023|cit23","first-page":"21","article-title":"Response to terlipressin and albumin is associated with improved outcome in patients with cirrhosis and hepatorenal syndrome","volume":"140","author":"Nguyen-Tat","year":"2015","journal-title":"Deutsche Medizinische Wochenschrift"},{"key":"10.1002\/14651858.CD005162.pub4-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1053\/jhep.2003.50276","article-title":"Octreotide in hepatorenal syndrome: a randomized, double-blind, placebo-controlled, crossover study","volume":"38","author":"Pomier-Layrargues","year":"2003","journal-title":"Hepatology (Baltimore, Md.)"},{"key":"10.1002\/14651858.CD005162.pub4-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1111\/j.1572-0241.2008.01828.x","article-title":"An open label, pilot, randomized controlled trial of noradrenaline versus terlipressin in the treatment of type 1 hepatorenal syndrome and predictors of response","volume":"103","author":"Sharma","year":"2008","journal-title":"American Journal of Gastroenterology"},{"key":"10.1002\/14651858.CD005162.pub4-BIB0026|cit26","first-page":"449A","article-title":"Noradrenaline versus terlipressin in the treatment of type 1 hepatorenal syndrome: a randomized controlled trial","volume":"44","author":"Sharma","year":"2006","journal-title":"Hepatology (Baltimore, Md.)"},{"issue":"11","key":"10.1002\/14651858.CD005162.pub4-BIB0027|cit27","first-page":"1946","article-title":"Efficacy of terlipressin and albumin in the treatment of hepatorenal syndrome","volume":"12","author":"Silawat","year":"2011","journal-title":"World Applied Sciences Journal"},{"key":"10.1002\/14651858.CD005162.pub4-BIB0028|cit28","first-page":"35","article-title":"A comparative study of high- or low-dose terlipressin therapy in patients with cirrhosis and type 1 hepatorenal syndrome","volume":"21","author":"Wan","year":"2014","journal-title":"Zhonghua Gan Zang Bing Za Zhi"},{"key":"10.1002\/14651858.CD005162.pub4-BIB0029|cit29","unstructured":"A placebo-controlled, double-blind study to confirm the reversal of hepatorenal syndrome type 1 with terlipressin Ongoing study September 2010"},{"key":"10.1002\/14651858.CD005162.pub4-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1016\/j.jhep.2014.12.029","article-title":"Diagnosis and management of acute kidney injury in patients with cirrhosis: revised consensus recommendations of the International Club of Ascites","volume":"62","author":"Angeli","year":"2015","journal-title":"Journal of Hepatology"},{"key":"10.1002\/14651858.CD005162.pub4-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1002\/hep.510230122","article-title":"Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. International Ascites Club","volume":"23","author":"Arroyo","year":"1996","journal-title":"Hepatology (Baltimore, Md.)"},{"key":"10.1002\/14651858.CD005162.pub4-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1136\/bmj.38987.492014.94","article-title":"How to formulate research recommendations","volume":"333","author":"Brown","year":"2006","journal-title":"BMJ (Clinical Research Ed.)"},{"key":"10.1002\/14651858.CD005162.pub4-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/S1665-2681(19)32154-4","article-title":"Hepatorenal syndrome","volume":"2","author":"Cardenas","year":"2003","journal-title":"Annals of Hepatology"},{"issue":"1","key":"10.1002\/14651858.CD005162.pub4-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1007\/s11255-010-9725-8","article-title":"Terlipressin in hepatorenal syndrome: a systematic review and meta-analysis","volume":"43","author":"Dobre","year":"2011","journal-title":"International Urology and Nephrology"},{"key":"10.1002\/14651858.CD005162.pub4-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1177\/039139880903200303","article-title":"Terlipressin for hepatorenal syndrome: a meta-analysis of randomized trials","volume":"32","author":"Fabrizi","year":"2009","journal-title":"International Journal of Artificial Organs"},{"key":"10.1002\/14651858.CD005162.pub4-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/S0140-6736(82)91689-0","article-title":"Controlled trial of terlipressin ('Glypressin') versus vasopressin in the early treatment of oesophageal varices","volume":"2","author":"Freeman","year":"1982","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD005162.pub4-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"2064","DOI":"10.1002\/hep.22605","article-title":"Acute kidney injury and cirrhosis","volume":"48","author":"Garcia-Tsao","year":"2008","journal-title":"Hepatology (Baltimore, Md.)"},{"key":"10.1002\/14651858.CD005162.pub4-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/0016-5085(93)90031-7","article-title":"Incidence, predictive factors, and prognosis of hepatorenal syndrome in cirrhosis","volume":"105","author":"Gines","year":"1993","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD005162.pub4-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1016\/S0140-6736(03)14903-3","article-title":"Hepatorenal syndrome","volume":"362","author":"Gines","year":"2003","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD005162.pub4-BIB0040|cit40","unstructured":"Gluud C Nikolova D Klingenberg SL Cochrane Hepato-Biliary Group About Cochrane (Cochrane Review Groups (CRGs)) 2017, Issue 1. Art. No.: LIVER"},{"key":"10.1002\/14651858.CD005162.pub4-BIB0041|cit41","unstructured":"Brozek J Oxman A Sch\u00fcnemann H GRADEpro 2008"},{"key":"10.1002\/14651858.CD005162.pub4-BIB0042|cit42","unstructured":"Higgins JP Green S editor(s) Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from handbook.cochrane.org"},{"key":"10.1002\/14651858.CD005162.pub4-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1056\/NEJM200105243442106","article-title":"Is the placebo powerless? An analysis of clinical trials comparing placebo with no treatment","volume":"344","author":"Hr\u00f3bjartsson","year":"2001","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD005162.pub4-BIB0044|cit44","volume-title":"International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. ICH Harmonised Tripartite Guideline. Guideline for Good Clinical Practice CFR & ICH Guidelines","volume":"1","author":"International Conference on Harmonisation Expert Working Group","year":"1997"},{"issue":"2","key":"10.1002\/14651858.CD005162.pub4-BIB0045|cit45","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD011532","article-title":"Terlipressin versus other vasoactive drugs for hepatorenal syndrome","author":"Israelsen","year":"2015","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD005162.pub4-BIB0046|cit46","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1111\/jgh.12709","article-title":"Acute kidney injury and hepatorenal syndrome in cirrhosis","volume":"30","author":"Israelsen","year":"2015","journal-title":"Journal of Gastroenterology and Hepatology"},{"key":"10.1002\/14651858.CD005162.pub4-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1007\/s12325-008-0118-7","article-title":"Efficacy and safety of terlipressin in cirrhotic patients with variceal bleeding or hepatorenal syndrome","volume":"25","author":"Krag","year":"2008","journal-title":"Advances in Therapy"},{"key":"10.1002\/14651858.CD005162.pub4-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1111\/j.1365-2036.2004.02112.x","article-title":"Review article: pathogenesis and pathophysiology of hepatorenal syndrome--is there scope for prevention?","volume":"20","author":"Moller","year":"2004","journal-title":"Alimentary Pharmacology & Therapeutics"},{"key":"10.1002\/14651858.CD005162.pub4-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1592\/phco.24.11.1050.36144","article-title":"The role of vasopressin in vasodilatory septic shock","volume":"24","author":"Obritsch","year":"2004","journal-title":"Pharmacotherapy"},{"key":"10.1002\/14651858.CD005162.pub4-BIB0050|cit50","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1159\/000044879","article-title":"Circadian rhythm of arginine vasopressin in hepatorenal syndrome","volume":"78","author":"Pasqualetti","year":"1998","journal-title":"Nephron"},{"key":"10.1002\/14651858.CD005162.pub4-BIB0051|cit51","unstructured":"The Nordic Cochrane Centre, The Cochrane Collaboration Review Manager (RevMan) 2014"},{"issue":"4","key":"10.1002\/14651858.CD005162.pub4-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1017\/S0266462303000552","article-title":"Literature searching for randomized controlled trials used in Cochrane reviews: rapid versus exhaustive searches","volume":"19","author":"Royle","year":"2003","journal-title":"International Journal of Technology Assessment in Health Care"},{"key":"10.1002\/14651858.CD005162.pub4-BIB0053|cit53","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1002\/hep.20766","article-title":"Circulatory function and hepatorenal syndrome in cirrhosis","volume":"42","author":"Ruiz-del-Arbol","year":"2005","journal-title":"Hepatology (Baltimore, Md.)"},{"key":"10.1002\/14651858.CD005162.pub4-BIB0054|cit54","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1111\/j.1440-1746.2009.06132.x","article-title":"Terlipressin therapy for reversal of type 1 hepatorenal syndrome: a meta-analysis of randomized controlled trials","volume":"25","author":"Sagi","year":"2010","journal-title":"Journal of Gastroenterology and Hepatology"},{"key":"10.1002\/14651858.CD005162.pub4-BIB0055|cit55","first-page":"1310","article-title":"Diagnosis, prevention and treatment of hepatorenal syndrome in cirrhosis","volume":"56","author":"Salerno","year":"2007","journal-title":"Gut"},{"key":"10.1002\/14651858.CD005162.pub4-BIB0056|cit56","first-page":"1","article-title":"Influence of reported study design characteristics on intervention effect estimates from randomised controlled trials: combined analysis of meta-epidemiological studies","volume":"16","author":"Savovi\u0107","year":"2012","journal-title":"Health Technology Assessments"},{"key":"10.1002\/14651858.CD005162.pub4-BIB0057|cit57","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1002\/hep.20044","article-title":"Worsening of cerebral hyperemia by the administration of terlipressin in acute liver failure with severe encephalopathy","volume":"39","author":"Shawcross","year":"2004","journal-title":"Hepatology (Baltimore, Md.)"},{"key":"10.1002\/14651858.CD005162.pub4-BIB0058|cit58","unstructured":"Stata Corp STATA 2007"},{"key":"10.1002\/14651858.CD005162.pub4-BIB0059|cit59","unstructured":"Copenhagen Trial Unit TSA - Trial Sequential Analysis 2011"},{"key":"10.1002\/14651858.CD005162.pub4-BIB0060|cit60","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1136\/bmj.39465.451748.AD","article-title":"Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study","volume":"336","author":"Wood","year":"2008","journal-title":"BMJ (Clinical Research Ed.)"},{"issue":"4","key":"10.1002\/14651858.CD005162.pub4-BIB0061|cit61","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD005162","article-title":"Terlipressin for hepatorenal syndrome","author":"Gluud","year":"2006","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"2","key":"10.1002\/14651858.CD005162.pub4-BIB0062|cit62","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1002\/hep.23286","article-title":"Systematic review of randomized trials on vasoconstrictor drugs for hepatorenal syndrome","volume":"51","author":"Gluud","year":"2010","journal-title":"Hepatology (Baltimore, Md.)"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1002\/14651858.CD005162.pub4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,2]],"date-time":"2024-01-02T08:48:33Z","timestamp":1704185313000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD005162.pub4"}},"subtitle":[],"editor":[{"name":"Cochrane Hepato-Biliary Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2017,6,14]]},"references-count":62,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2017,6]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd005162.pub4","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,6,14]]}}}